Skip to content

Assesment of Lactulose vs Lactobacillus Acidophilus Effect in CKD Patients

Assesment of Lactulose vs Lactobacillus Acidophilus Effect in CKD Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05934552
Enrollment
150
Registered
2023-07-07
Start date
2023-12-31
Completion date
2024-12-31
Last updated
2023-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CKD

Brief summary

Assessment for usage of laxatives and probiotics ,and its role in improving uremic parameters of CKD as GFR, UREA ,CREATININE, CLINICAL and UREMIC assessment (lower limb edema ,UOP,base of chest ,vomiting ,dyspnea,blood pressure measurement)

Detailed description

with advanced CKD stages ,also have been linked to the high prevalence of constipation in CKD,Lactulose is a synthetic disaccharide.Lactulose is poorly absorbed from the gastrointestinal tract remains virtually unchanged and is then fermented by gut microbiota that increase osmotic effects and intraluminal gas formation . lactulose reduces the nitrogen products and urea, creatinine, uric acid, and b2- microglobulin levels. Lactulose also suppress tubulointerstitial fibrosis in a rat model of a kidney disease study . Lactulose modifies the gut microbiota, increasing the abundance of Bifidobacteria and Lactobacilli after 8 weeks of 30 ml lactulose syrup thrice daily, and ameliorates CKD progression by suppressing uremic toxin production .probiotics include vast array of products with living organisms whose purpose is to improve intestinal microbial balance and produce beneficial effect on ones health .probiotics is an alternative therapy for patients with CKD

Interventions

DRUGLactulose

lactulose and lactobacillus acidophilus on ckd patients

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* CKD stages 3,4,5 with non-dialysis receiving a diagnosis of constipation * DM nephropathy

Exclusion criteria

* IBS (ulcerative colitis -crohns) * HCV ,HBV , * autoimmune patients, * malignancy pt * cirrhotic patients * haemodialysis patients * cardiovascular patients * abdominal surgery, * gut obstruction, * pregnancy, * patients with ESRD on dialysis, * history of lactulose allergy.

Design outcomes

Primary

MeasureTime frameDescription
Assessment for usage of laxatives and probiotics ,and its role in improving uremic parameters in CKD patients and compare between both.1 yearAssessment for usage of laxatives and probiotics ,and its role in improving uremic parameters in CKD patients and compare between both.

Contacts

Primary Contactabdelrahamn abo bakr mokhtar, resident doctor
abdousaad95@gmail.com+2001010180714

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026